Cohen, S.B., Moreland, L.W., Cush, J.J., Greenwald, M.W., Block, S., Shergy, W.J., Hanrahan, P.S., Kraishi, M.M., Patel, A., Sun, G. and Bear, M.B. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotreksate. Annals of the Rheumatic Diseases, 63, 1062-1068. doi:10.1136/ard.2003.016014

has been cited by the following article:

• TITLE: The interleukin-1 receptor antagonist (IL-1-Ra) and soluble tumor necrosis factor receptor I (sTNF RI) in periodontal disease

  AUTHORS: Sylwia M. Slotwinska

  KEYWORDS: Periodontitis; Interleukin-1 Receptor, Antagonist (IL-1 Ra); Soluble Tumor Necrosis, Factor Receptor I (sTNF RI)

  JOURNAL NAME: Open Journal of Immunology, Vol.3 No.1, March 13, 2013

  ABSTRACT: The course and severity of periodontitis can be significantly affected by bacterial virulence as well as host immunity dysfunction. Periodontal tissue destruction has been proved to result from cascade of cytokines synthesized by reactive cells upon stimulation by pathogenic bacteria and lipopolysaccharides within their cell membranes. The clinical use of genetically programmed cells, producing substances blocking IL-1, based on recombinant IL-1 antagonist, as well as cytokines activating fibroblasts and osteoblasts to regenerate the destroyed periodontal tissue could prove alternative to the conventional treatment. Another cytokine of interest in respect to periodontitis ethiopathogenesis is soluble tumor necrosis factor receptor I (sTNF RI). Observation of soluble TNF receptors as physiologic inhibitors of TNF led to its administration in therapeutic process as well as in therapy selected cases of aggressive periodontitis.